With the acquisition of BSD Medical hyperthermia assets, Pyrexar Medical takes its place as pioneer and worldwide market leader in the development and manufacture of innovative and highly effective hyperthermia treatment systems with established distribution and support networks in the US, Europe and Asia. PYREXAR HyperThermia (PYREXAR HT) treatments increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity of healthy tissues. PYREXAR systems deliver therapeutic heating via non-invasive radio-frequency (RF) energy. During superficial, interstitial, or deep regional hyperthermia treatment, the cancerous tumor is gently warmed to 40-45 degrees C (104-113 degrees F) destroying malignant cells while preserving normal tissues because higher temperatures selectively damage cells that are hypoxic and have a low pH, a condition of cancer cells that is not present in normal cells. Multi-center clinical trials in the US, Europe and Asia over the past 30 years documen
Explore 50 technologies across 16 categories that Pyrexar Medical uses
Pyrexar Medical headquarters are located at United States.
The official website of Pyrexar Medical is https://pyrexar.com/.
Slintel keeps track of 11-50 employees who are working at Pyrexar Medical.
Pyrexar Medical is in the industry of Medical Devices.
*All data and insights on this page are captured, aggregated, and regularly updated by Slintel